Serum levels of sICAM-1, TNFα, sTNF-R1, and sTNF-R2 in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin

Experimental and Clinical Hepatology

Volumn 4, Issue 1, 2008, Pages 12-20

  Kukla, Michał ^a   Warakomska, Iwona ^a   Gabriel, Andrzej ^a   Zwirska Korczala, Krystyna ^a   Rybus Kalinowska, Barbara ^a   Berdowska, Agnieszka ^b   Kalinowski, Mariusz ^a   Chwist, Alina ^a   Waluga, Marek ^a   Kuka, Dorota ^a   Kȩpa, Lucjan ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

Chronic hepatitis C; Inflammatory activity; Soluble intercellular adhesion molecule 1; Tumor necrosis factor ; Tumor necrosis factor receptors

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; PEGINTERFERON ALPHA2A; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; MALE; OXIDATIVE STRESS; PATHOGENESIS; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION;

EID: 70449588196     PISSN: 17343038     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Lalor PF, Shileds P, Crant AJ, Adams DH: Recruinnent of lymphocytes to the human liver Immunology and Cell Biology 2002; 80: 52-64.
2. Ziolkowski A, Wylezol M, Kukla M et al: Factors associated with steatosis and necroinfiammatory activity in morbidly obese patients with non-alcoholic fatty liver disease. Pol J Environ Stud 2005; 14 suppl. 2, 417-20.
3. Brillanti S, Foli M, Gaiani S, Masci C, Miglioli M, Barbata L: Persistent hepatitis C viraemia without liver disease. Lancet 1993; 341: 464-65.
4. Koziel MJ, Duddley D, Wong JT et al: Intrahepatic cytotoxic T lyrnphocytea specific for hepatitis virus in persons with chronic hepatitis. J Immunol 1992; 149: 3339-44.
5. Ley K: Molecular mechanisms of leukocyre recruitment in the inflammatory process. Cardiovasc Res 1996; 32: 733-42.
6. Gonzalez-Amaro R, Diaz-Gonzalaz F, Sanchez-Madrid F: Adhesion molecules in inflammatory diseases. Drugs 1998; 56: 977-88.
7. Zwirska-Korczla K, Kukla M, Ziolkowski A et al: Association of serum sVCAM-1 concentration with fibrosis stage and inflammatory activity grade in chronic hepatitis C patients. EC Hepatology 2006; 2(2), 60-64.
8. Zwirska-Korczla K, Kukla M, Ziolkowski A et al: The usefulness of sPECAM-1 (sCD 31) serum concentration measurement in chronic hepatitis C. EC Hepatology 2006; 2(2), 55-69.
9. Gearing AJH, Newman W: Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-12.
10. Hordjik PL: Endothelial signaling events during leukocyte transmigration. FEBSJ 2006; 273, 4408-15.
11. Engelhardt B, Wolburg H: Trans-endothelial migration of leukocytes: through the front door or around the side of the house? Fur J Immunol 2004; 34, 2955-63.
12. Petri B, Bixel MC: Molecular events during leukocyte diapedesis. FEBS J 2006; 273; 4399-407.
13. Kakkar AK, Lefer DJ: Leukocyte and endothelial adhesion molecule studies in knockout mice. Curr Opin Pharmacol 2004; 4, 154-58.
14. Cerny A, Mc Hudchtson JG, Pasquinelli C et al: CytotoxicT lymphocyte response to hepatitis C virus - derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995; 95, 521-50.
15. Ballardini G, Gruff P. Pontisso P et al: Hepatitis C (HCV) virus genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment patients with chronic hepatitis C. J Clin Invest 1995; 95:2067-75.
16. Montalto G, Giannitrapani L, Soresi M et al: Circulating intercellular adhesion molecule-1 in chronic hepatitis C patients with normal or elevated aminotranslerase before and alter alpha-interferon treatment. Intervirology 2003, 46(1): 35-42.
17. Dejica D, Grigorescu M, Dejica V et al: Serum levels of soluble intercellular-1 and vascular cell-1 adhesion molecules in chronic hepatitis C and the influence of interferon-alpha + ribavirin therapy. Rom J Casiroenterol 2002; 11: 27743.
18. Granot E, Shouval D, Ashur Y: Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients. Mediators Inflamm 2001; 10: 253-58.
19. Bruno CM, Sciacca C, Cilio D et al: Circulating adhesion molecules in patients with virus-related chronic diseases of the liver World J Gastroenterol 2005; 11(29): 4566-69.
20. Nouri-Aria KT, Koskinas J, Tibbs CJ et al: Serum intercellular adhesion molecule-1 levels in chronic hepatitis C: association with disease activity and response to interferon alpha Gut 1995; 36, 599-603.
21. Lo lacono O, Garcia-Monzon C, Almasio P, Garcia-Buey L, Craxi A, Moreno-Otero R: Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-α. Aliment Pharmacol Ther 1998; 12: 1091-99.
22. Marui A, Fukuda Y, Koyama Y et al: Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in liver disease, and their changes by treatment with interferon. J Int Med Res 1996; 24: 258-65.
23. Fukuda Y, Nakano I, Katano Y, Marui A, Hayakawa T: Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in asymptomatic carriers of hepatitis C virus. J Int Med Res 1998; 26: 313-18.
24. Kaplanski G, Farnarier C, Payan MJ, Bongrand P, Durand JM: Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis. Dig Dis Sci 1997; 42: 2277-84.
25. Bagnasco M, Riccio AM, Sinelli N et al: Serum intercellular adhesion molecule-1 and long-term response to IFN - alpha 2b therapy in chronic hepatitis C.J Interferon Cytokine Res 1998; 18: 963-66.
26. Capra F, De Maria E, Lunardi C et al: Seruns level of soluble intercellular adhesion molecule-1 in patients with chronic liver disease related to hepatitis C virus. A prognostic marker for response to interferon treatment. J Infect Dis 2000; 181: 425-31.
27. Wang H, Czura CJ, Tracey KJ: Tumor necrosis factor. In: The Cytokine Handbook, 4th Edition, Thomson AW, Lotze MT, eds. Elsevier Science Ltd London. 2003 pp. 837-60.
28. Zylberbetg H, Rimaniol AC, Pol S et al: Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999; 30: 185-91.
29. Larrea E, Garcia N, Qian Ch, Civeira MP. Prieto J: Tumor necrosis factor α gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23: 210-17.
30. Yoon JH, Cores GJ: Death receptor - mediated apoptosis and the liver J Hepatol 2002; 37: 400-10.
31. Ding WX, Yin XM: Dissection of the multiple mechanisms of TNF α-induced apoptosis in liver injury. J Cell Mol Med 2004; 8(4): 445-54.
32. Scheuer PJ: The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995; 22: 112-14.
33. Gabriel A, Ziolkowski A: New terminology of chronic hepatitis, including a scoring scale. Med Sci Monit 1997; 3 113-18.
34. Banner BF, Allan C, Savas L et al: Inflammatory markers in chronic hepatitis C. Virclsows Arch 1997,431, 181-87.
35. Pigott R, Dillon LP, Hemingway IH, Gearing AJH: Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatant of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187; 584-89.
36. Hillan KJ. Hagler KE. MacSween RN et al: Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease. Liver 1999; 19(6): 509-18.
37. Taliani G, Badolato MC, Born A et al: HCV infection of peripheral blood mononuclear cells and levels of soluble ICAM-1 in patients treated with interferon. Arch Virol 1997; 142: 557-65.
38. Garcia-Monzon C, Garcia-Buey L, Garcia-Sanchez AS, Pajares JM, Moreno-Otero R: Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interfon alfa-2b. Gastroenterology 1993; 105:462-69.
39. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW: ICAM-1 regulates neutrophil adhesion and trasnscellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 2005; 106:584-92.
40. Ghavami S, Hashemi M, Kadkheda K, Alavian SM. Bay GH, Los M: Apoptosis in liver diseases-detection and therapeutic applications. Med Sci Monit 2005; 11(11): RA337-45.
41. Kishihara Y, Hayashi J, Yoshimura E, Yamaji K, Nakashima K, Kashiwagi S: II-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996; 41(2): 315-21.
42. Panasiuk A, Pogorzelska J, Prokopowicz D: Growth factors in chronic hepatitis C. Przegl Epidemiol 2007; 6 1(3): 559-66.
43. Nelson DR. Lim HL, Marousis C.G et al: Activation of tumor necrosis factor-α system in chronic hepatitis C virus infection. Dig Dis Scien 1997; 42(12): 2487-94.
44. Nagai H, Matsumaru K, Feng G, Kaplowitz N: Reduced glurathione depletion causes necrosis and sensitization to tumor necrosis factor- alpha-induced apoptosis in cultured morse hepatocytes. Hepatology 2002; 36: 55-64.
45. Martsumaru K, Ji C, Kaplowitz N: Mechanisms for sensitization to TNF-induced apoprosts by acute glutarhione depletion in murine hepatocytes. Hepatology 2003; 37: 1425-34.
46. Mita E, Hayashi N, Hagiwara H et al: Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 97742.
47. Kallinowski B, Haseroth K, Marinos G, et al: Induction of tumor necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998; 111(2): 269-77.
48. Kakumu S, Okumura A, Ishikawa T et al: Serum levels of I1-10,I1-15 and soluble tumor necrosis factor-alpha (TNF-α) receptors in type C chronic liver disease. Clin Exp Immunol 1997; 109(3): 458-63.
49. Tilg H, Vogel W, Dinarello ChA: Interferon-α induces circulating tumor necrosis factor receptor p55 in humans. Blood 1995,85(2): 433-35.
50. Torre F, Rossol S, Pelli N, Basso M, Delfino A, Picciotto A: Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. Clin Exp Immunol 2004; 136(3): 507-12.